WOODCLIFF LAKE, N.J., June 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. and PLIVA d.d. (All figures provided in U.S. Dollars) Fact Sheet Barr * PLIVA ** Revenues $1.24 Billion $1.174 Billion Net Income $335.1 Million $223.4 Million EBIT $495.1 Million $247.9 Million EBITDA $547.6 Million $336.4 Million Cash and Marketable $612.8 Million $296.9 Million Securities Shares Outstanding 108.5 Million 18.6 Million Market Capitalization $5.4 Billion $1.9 Billion (Current) R&D Expense $132.6 Million $73.6 Million Key Markets USA, Canada USA, Croatia, Poland, Russia, Germany, UK, Italy, Spain Product Portfolio 76 Generic, Generic, OTC, 19 Brand Including Cytostatics, APIs SEASONALE(R) Extended-Cycle Oral Contraceptive, SEASONIQUE(TM) Extended-Cycle Oral Contraceptive, ParaGard(R) IUD, ENJUVIA(TM) Hormone Therapy Pipeline 39 ANDAs at U.S. FDA 21 ANDAs at U.S. FDA 2 NDAs at U.S. FDA 120 Generic Development 50 Generic Development Products (70 Individual Products Molecules) 8 Brand Development 2 Disclosed Bio-Generic Products Projects; Several 1 Disclosed Others In Development Bio-Generic Project; 2 In Development Sales Forces 250 Person Female 1,400 Sales and Healthcare Sales Force Marketing and 103 Person People Worldwide Specialty Sales Force Promote Branded-Generic Promote Branded Products Products Therapeutic Female Healthcare, Anti-Infectives, Categories Oncology, Injectables, Cardiovascular, Cytostatics, APIs, Anti-Infectives, Diuretics, Psycho-therapeutics Nutraceuticals Headquarters Woodcliff Lake, NJ Zagreb, Croatia Facilities New York, New Jersey, Zagreb, Croatia; Pennsylvania, Krakow, Poland; Brno, Virginia, Ohio, Czech Republic; Goa, Washington, DC India; New Jersey, USA Number of Employees Approx. 2,000 Approx. 6,000 * Barr financial figures are for the 12 months ended March 31, 2006 (Barr’s fiscal 2006 will end June 30, 2006) and exclude non-recurring items. ** PLIVA financial figures are for the 12 months ended December 31, 2005 and exclude discontinuing operations and restructuring charges. Company Descriptions: Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. , a holding company that operates through its principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals.
PLIVA d.d.
PLIVA , established in 1921, is headquartered in Zagreb, Croatia. A global generic pharmaceutical company with operations in more than 30 countries worldwide, PLIVA is currently the leading pharmaceutical company based in Central and Eastern Europe (CEE).
Forward-Looking Statements
Except for the historical information contained herein, the statements made in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by their use of words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates” and other words of similar meaning. Because such statements inherently involve risks and uncertainties that cannot be predicted or quantified, actual results may differ materially from those expressed or implied by such forward-looking statements depending upon a number of factors affecting the Company’s business. These factors include, among others: the difficulty in predicting the timing and outcome of legal proceedings, including patent-related matters such as patent challenge settlements and patent infringement cases; the outcome of litigation arising from challenging the validity or non- infringement of patents covering our products; the difficulty of predicting the timing of FDA approvals; court and FDA decisions on exclusivity periods; the ability of competitors to extend exclusivity periods for their products; our ability to complete product development activities in the timeframes and for the costs we expect; market and customer acceptance and demand for our pharmaceutical products; our dependence on revenues from significant customers; reimbursement policies of third party payors; our dependence on revenues from significant products; the use of estimates in the preparation of our financial statements; the impact of competitive products and pricing on products, including the launch of authorized generics; the ability to launch new products in the timeframes we expect; the availability of raw materials; the availability of any product we purchase and sell as a distributor; the regulatory environment; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies and products we acquire and implementing our new enterprise resource planning system; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; changes in generally accepted accounting principles; and other risks detailed from time-to-time in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the fiscal year ended June 30, 2005.
The forward-looking statements contained in this press release speak only as of the date the statement was made. The Company undertakes no obligation (nor does it intend) to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required under applicable law.
Barr Pharmaceuticals, Inc.
CONTACT: Carol A. Cox of Barr Pharmaceuticals, Inc., +1-201-930-3720,ccox@barrlabs.com
Web site: http://www.barrlabs.com/
Company News On-Call: http://www.prnewswire.com/comp/089750.html/
